1106 CLINICAL AND MULTIMODAL IMAGING FOLLOW-UP OF PATIENTS WITH MYOPERICARDITIS FOLLOWING MRNA COVID-19 VACCINATION


 
 
 Myopericarditis following coronavirus disease-2019 (COVID-19) vaccine is a described entity, but its evolution is still unclear.
 
 
 
 Patients with a diagnosis of myopericarditis after mRNA COVID-19 vaccine represented our population. Clinical evaluation, laboratory tests and non-invasive cardiac tests were performed at baseline and at six months.
 
 
 
 Between January and August 2021, we identified 7 patients with myopericarditis following mRNA vaccination. The median age was 29 years (IQR: 25.5–53.5 years) and all patients were males. The median time from vaccine administration to symptoms onset was 5 days (IQR: 4–7 days); five patients received BNT162b2, two mRNA-1273 and only one patient developed symptoms after first dose of vaccine. The most common symptoms at presentation were chest pain (100%) and fatigue (71.4%). Left Ventricular Ejection Fraction (LVEF) was preserved in 6 of them while was mildly reduced in one (median LVEF: 61.3% [IQR: 60–62.9%]). Late Gadolinium Enhancement was detected at Cardiac Magnetic Resonance in the 42.9% of cases. Treatment was conservative for all patients except one; a pericardiocentesis was necessary due to massive pericardial effusion.
 At six months follow-up all patients were asymptomatic with normal troponin level, electrocardiogram and echocardiogram confirming the complete healing of the inflammatory process. Two patients received a COVID-19 vaccine booster dose without evidence of myopericardial involvement.
 
 
 
 Myopericarditis associated with mRNA COVID19 vaccination is more frequent in young males and is usually characterized by a benign evolution.
